Clinical Trial Update: Korean Regulatory Post Marketing Surveillance for Somavert

View source ↗

Summary

A Korean regulatory post-marketing surveillance study of Somavert (pegvisomant) in acromegaly is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Somavert (pegvisomant)

Snippet

Sponsor: Pfizer | Conditions: Acromegaly | Status: RECRUITING